Salt Lake City, Utah, U.S., September 17, 2026
Co-Diagnostics, Inc., a molecular diagnostics company developing technologies for infectious disease testing, is participating in the Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting, taking place September 17–18, 2026. The meeting brings together stakeholders involved in global health, diagnostics, infectious disease programs, and access to testing. Co-Diagnostics’ participation highlights the company’s ongoing engagement with organizations working to expand molecular diagnostic access and testing capabilities, particularly in settings where decentralized and near-point-of-care technologies may be needed.
Co-Diagnostics Engages With Global Health Stakeholders
The WHO, Unitaid, and UNAIDS annual consultation provides an opportunity for organizations involved in diagnostics and global health to discuss priorities affecting access to testing and healthcare technologies. Co-Diagnostics is participating as part of its broader efforts to advance molecular diagnostic solutions that can potentially be deployed beyond conventional laboratory environments. Co-Diagnostics develops molecular diagnostic technologies based on the detection and analysis of DNA and RNA molecules. The company has developed its proprietary Co-Dx PCR platform with the goal of supporting molecular testing in decentralized settings. Its participation in the consultation comes as international health organizations continue to focus on improving access to diagnostics for infectious diseases and strengthening health systems.
The company’s recent activities have included work involving tuberculosis, Ebola, and other infectious diseases, as well as efforts to expand its diagnostic infrastructure internationally. Co-Diagnostics has also participated in global diagnostic workshops and collaborations focused on near-point-of-care testing.
Focus on Accessible Molecular Diagnostic Testing
Advertisement
A key area of Co-Diagnostics’ technology strategy is bringing molecular testing closer to patients. Conventional PCR testing can require centralized laboratory infrastructure, specialized equipment, and trained personnel. Point-of-care and near-point-of-care molecular diagnostics are being developed to help perform testing in settings that may have more limited laboratory resources.Co-Diagnostics has been advancing its Co-Dx PCR platform for decentralized testing applications. The company has stated that the platform is designed around molecular diagnostic workflows that can support testing outside traditional centralized laboratories, although regulatory status varies by individual product and application.
The company has also been evaluating expanded applications for its technology. On September 16, 2026, Co-Diagnostics announced a collaboration with ReadyGo Diagnostics to evaluate blood-based molecular testing at the point of need, initially focusing on Ebola detection. The companies are assessing whether ReadyGo’s GoCollect sample-preparation technology can be integrated with Co-Dx PCR technology for decentralized blood-based molecular testing. The evaluation could potentially broaden the range of specimen types and infectious diseases addressed by the platform, although Co-Diagnostics has emphasized that compatibility remains subject to feasibility work and that there is no assurance the evaluation will result in a commercially available product.
Co-Diagnostics Advances International Diagnostics Strategy
Co-Diagnostics’ participation in the consultation is part of a broader international strategy involving infectious disease diagnostics and decentralized testing. The company has recently pursued initiatives involving tuberculosis testing in India and near-point-of-care diagnostic implementation discussions in Southeast Asia. In September, the company also announced the launch of integrated cloud and mobile infrastructure in India to support ongoing clinical studies for its Mycobacterium tuberculosis (MTB) test and potential future deployment of its technology in the country. Earlier in 2026, Co-Diagnostics participated in a United Nations Office for Project Services workshop in Bangkok focused on near-point-of-care tuberculosis diagnostics. The workshop brought together national TB programs, reference laboratories, researchers, donors, and technical agencies from multiple countries to discuss implementation of WHO-recommended diagnostic approaches.
These activities demonstrate the company’s continuing focus on global molecular diagnostics, particularly technologies intended for use in decentralized or resource-limited environments. Participation in the WHO/Unitaid/UNAIDS consultation gives Co-Diagnostics an additional opportunity to engage with stakeholders involved in international health programs and diagnostic access. The September 17–18 meeting therefore represents another step in Co-Diagnostics’ engagement with the global health and diagnostics community. As countries and international organizations work to strengthen infectious disease surveillance and expand access to testing, molecular diagnostics, point-of-care technologies, and decentralized testing platforms remain important areas of development.
Source: Co-Diagnostics press release
